SELECT Trial: The Evidence for CV Coverage The SELECT trial (published in NEJM, November 2023) demonstrated that Wegovy reduces cardiovascular events: [27] 20% reduction in major adverse cardiovascular events (MACE) Includes heart attacks, strokes, and cardiovascular death 17,604 participants followed for ~3.3 years All participants had established cardiovascular disease plus obesity/overweight Typical Plan Coverage Criteria for CV Indication Medicare plans that cover Wegovy for cardiovascular risk reduction typically require: Clinical Criteria Established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease) BMI (body mass index) 27 kg/m No Type 2 diabetes (or T2D not adequately controlled) Concurrent lifestyle modifications (diet and exercise) Required Documentation Cardiology records documenting established CVD Current BMI (height and weight within last 30 days) Letter of Medical Necessity from cardiologist or primary care provider Documentation of lifestyle modification attempts ICD-10 Codes for CV vs
Most patients achieve their desired results with one-hand filler treatment
This ensures you understand the correct medication, dosage and administration method for your medication
Para dulaglutida y tirzepatida, generalmente se requieren 72 horas entre dosis
The mechanism of enhanced lignin regulating foliar Cd absorption and yield in rice (Oryza sativa L.)
The highest incidence of autism has been reported to be South Korea, where the incidence is now reported to be one in 38 boys
